EEF2K and Dravet syndrome: Finally, as a proof‐of‐concept study, we showed that the small‐molecule eEF2K inhibitor A484954 could rescue cognitive impairments and synaptic failure in DS model mice, suggesting targeting the eEF2K signaling could be a feasible therapeutic strategy for aging‐related cognitive impairments in DS.